cancer doctors

Kidney Cancer

Question: How much protein per day for kidney cancer survivor? My sister is 50 years old. Three years ago, she had left kidney cancer and it was removed. Since that time, she's always afraid of eating whatever food which has protein in there, especially, meat and seafood because she thinks her remain kidney will be damage if she eats so much protein. So she just eat tofu, vegetable, fruit and around 4 ounces of fish or chicken breast every day and drink some soymilk with 1 once of protein powder. Anyone who know how much protein she should consume per day, please let us know. Your answers would be greatly appreciated.

Answer: It is better to avoid High protien foods specially for Kidney cancer survivors. A moderate amount of protien can be taken say daily about 20 grams. You are encouraged to eat foods that provide optimal nutritional benefit. A registered dietitian consults with you to develop an individualized meal plan. Selections include fish, poultry, legumes, low-fat yogurt, fruits and vegetables, whole grains and cereals, and other healthy food choices. Vitamin and mineral supplements help provide nutrients that your diet may not, and offer a boost where illness may have depleted your body. The CTCA supplementation plan includes nutrients that may support your immune system and may reduce toxic side effects. A physician will recommend daily dosages of various nutrients, including: -Beta carotene -Selenium -Vitamin C -Eicosapentaenoic acid (EPA) -Vitamin E -Others as appropriate The Oncologist who is treating may be consulted so that he can tell the exact food values and restriction as he will know the full condition of the patient and give or suggest correct amount of protien and others.-


Kidney Cancer News

Kidney Ca Drugs Worked Better Inside Trials

MedPage Today
Explain that metastatic kidney cancer patients deemed ineligible for targeted therapy clinical trials, but who still receive the trial treatment protocol in clinical practice, face a higher mortality risk. Point out that progression-free survival on ...
 

Kidney cancer

Body and Soul
Kidney cancer occurs when there's an uncontrollable growth of abnormal cells in one or both of the kidneys, which grow to form a tumor. The tumor can be benign (not cancerous) or malignant (cancerous). Benign lumps don't spread but malignant tumors can ...
 

Eureka! Science News

Certain Cancer Drugs May Have Fatal Side Effects: Analysis
U.S. News & World Report
 

Kuwait Times

FDA clears Pfizer drug for advanced kidney cancer
Wall Street Journal
 

Cabozantinib Shows Encouraging Activity in Heavily Pretreated Patients With ...

MarketWatch (press release)
Toni K. Choueiri, MD, Director of the Kidney Cancer Center at the Dana-Farber Cancer Institute, will present the data (Abstract #364) in a poster session at the 2012 Genitourinary Cancers Symposium at 6:45 am PST tomorrow in San Francisco.
 

Chronic Kidney Disease Linked to Higher Risk of Kidney and Urinary Tract Cancer

HealthCanal.com
Chronic kidney disease is associated with a higher risk of kidney and urothelial cancer, but not other types of cancer, according to research being presented this week at the American Society of Clinical Oncology's Genitourinary Cancers Symposium in ...
 

Kidney Cancer? There's a Drug for That

DailyFinance
The kidney cancer market is becoming increasingly crowded. Pfizer (NYS: PFE) just gained Food and Drug Administration approval of Inlyta last week, bringing the total drugs approved for the indication up to seven. Three of those -- Sutent, Torisel, ...
 

Advances and New Research in the Treatment of Kidney Cancer

Cancer Network
CancerNetwork speaks with Dr. Michael Atkins, leader of the kidney cancer program at the Dana-Farber Harvard Cancer Center and professor of medicine at the Beth Israel Deaconess Medical Center and Harvard School of Medicine.
 

Cabozantinib Shows Encouraging Activity In Heavily Pretreated Patients With ...

TheStreet.com (press release)
Toni K. Choueiri, MD, Director of the Kidney Cancer Center at the Dana-Farber Cancer Institute, will present the data (Abstract #364) in a poster session at the 2012 Genitourinary Cancers Symposium at 6:45 am PST tomorrow in San Francisco.
 

Early data show kidney cancer response to Exelixis' 'cabo'

Bizjournals.com (blog)
Exelixis Inc. 's experimental cancer drug cabozantinib showed promise in patients with a form of metastatic kidney cancer, according to a preliminary report from an early-stage trial. What's more, 19 of 21 patients in the trial showed tumor regression ...
 

Types of Cancer


Adrenal Cancer Anal Cancer Brain Cancer Colorectal Cancer Endometrial Cancer Esophageal Cancer
Esophageal Cancer Laryngeal Cancer Oral Cancer Penile Cancer Prostatic Cancer Stomach Cancer
Thyroid Cancer Bladder Cancer Bone Cancer Cervix Cancer Heart Cancer Kidney Cancer
Melanoma Cancer Pancreas Cancer Asbestos Cancer